Beam Therapeutics

Beam Therapeutics trended up intraday, closing at $35.17, up 5.05% from the prior close of $33.48, driven by recent clinical and regulatory progress. The FDA cleared the IND for its PKU candidate BEAM-304, while the BEACON trial data and partnership with AlphaDetect accelerated Alpha-1 detection. Q1 revenue reached $31.74 million, surging 324.87% YoY, with net loss narrowing 12.93% YoY. The stock is now 4.64% below its 52-week high of $36.88, but 125.45% above the 52-week low of $15.60, and trades above the MA20 ($32.42) and MA60 ($30.71), with a YTD gain of 29.59%. However, post-market activity saw the stock slip to $33.47, suggesting some profit-taking.